65
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: an open label, non-randomized, controlled study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Cardiovascular disease (CVD) is a leading cause of death among adults with type 2 diabetes mellitus (T2D). We recently reported that glycemic control in patients with T2D can be significantly improved through a continuous care intervention (CCI) including nutritional ketosis. The purpose of this study was to examine CVD risk factors in this cohort.

          Methods

          We investigated CVD risk factors in patients with T2D who participated in a 1 year open label, non-randomized, controlled study. The CCI group (n = 262) received treatment from a health coach and medical provider. A usual care (UC) group (n = 87) was independently recruited to track customary T2D progression. Circulating biomarkers of cholesterol metabolism and inflammation, blood pressure (BP), carotid intima media thickness (cIMT), multi-factorial risk scores and medication use were examined. A significance level of P < 0.0019 ensured two-tailed significance at the 5% level when Bonferroni adjusted for multiple comparisons.

          Results

          The CCI group consisted of 262 participants (baseline mean (SD): age 54 (8) year, BMI 40.4 (8.8) kg m −2). Intention-to-treat analysis (% change) revealed the following at 1-year: total LDL-particles (LDL-P) (− 4.9%, P = 0.02), small LDL-P (− 20.8%, P = 1.2 × 10 −12), LDL-P size (+ 1.1%, P = 6.0 × 10 −10), ApoB (− 1.6%, P = 0.37), ApoA1 (+ 9.8%, P < 10 −16), ApoB/ApoA1 ratio (− 9.5%, P = 1.9 × 10 −7), triglyceride/HDL-C ratio (− 29.1%, P < 10 −16), large VLDL-P (− 38.9%, P = 4.2 × 10 −15), and LDL-C (+ 9.9%, P = 4.9 × 10 −5). Additional effects were reductions in blood pressure, high sensitivity C-reactive protein, and white blood cell count (all P < 1 × 10 −7) while cIMT was unchanged. The 10-year atherosclerotic cardiovascular disease (ASCVD) risk score decreased − 11.9% (P = 4.9 × 10 −5). Antihypertensive medication use was discontinued in 11.4% of CCI participants (P = 5.3 × 10 −5). The UC group of 87 participants [baseline mean (SD): age 52 (10) year, BMI 36.7 (7.2) kg m −2] showed no significant changes. After adjusting for baseline differences when comparing CCI and UC groups, significant improvements for the CCI group included small LDL-P, ApoA1, triglyceride/HDL-C ratio, HDL-C, hsCRP, and LP-IR score in addition to other biomarkers that were previously reported. The CCI group showed a greater rise in LDL-C.

          Conclusions

          A continuous care treatment including nutritional ketosis in patients with T2D improved most biomarkers of CVD risk after 1 year. The increase in LDL-cholesterol appeared limited to the large LDL subfraction. LDL particle size increased, total LDL-P and ApoB were unchanged, and inflammation and blood pressure decreased.

          Trial registration Clinicaltrials.gov: NCT02519309. Registered 10 August 2015

          Electronic supplementary material

          The online version of this article (10.1186/s12933-018-0698-8) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references52

          • Record: found
          • Abstract: found
          • Article: not found

          Inflammation in atherosclerosis: from pathophysiology to practice.

          Until recently, most envisaged atherosclerosis as a bland arterial collection of cholesterol, complicated by smooth muscle cell accumulation. According to that concept, endothelial denuding injury led to platelet aggregation and release of platelet factors which would trigger the proliferation of smooth muscle cells in the arterial intima. These cells would then elaborate an extracellular matrix that would entrap lipoproteins, forming the nidus of the atherosclerotic plaque. Beyond the vascular smooth muscle cells long recognized in atherosclerotic lesions, subsequent investigations identified immune cells and mediators at work in atheromata, implicating inflammation in this disease. Multiple independent pathways of evidence now pinpoint inflammation as a key regulatory process that links multiple risk factors for atherosclerosis and its complications with altered arterial biology. Knowledge has burgeoned regarding the operation of both innate and adaptive arms of immunity in atherogenesis, their interplay, and the balance of stimulatory and inhibitory pathways that regulate their participation in atheroma formation and complication. This revolution in our thinking about the pathophysiology of atherosclerosis has now begun to provide clinical insight and practical tools that may aid patient management. This review provides an update of the role of inflammation in atherogenesis and highlights how translation of these advances in basic science promises to change clinical practice.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?

            Diabetes mellitus is a chronic condition that occurs when the body cannot produce enough or effectively use of insulin. Compared with individuals without diabetes, patients with type 2 diabetes mellitus have a considerably higher risk of cardiovascular morbidity and mortality, and are disproportionately affected by cardiovascular disease. Most of this excess risk is it associated with an augmented prevalence of well-known risk factors such as hypertension, dyslipidaemia and obesity in these patients. However the improved cardiovascular disease in type 2 diabetes mellitus patients can not be attributed solely to the higher prevalence of traditional risk factors. Therefore other non-traditional risk factors may be important in people with type 2 diabetes mellitus. Cardiovascular disease is increased in type 2 diabetes mellitus subjects due to a complex combination of various traditional and non-traditional risk factors that have an important role to play in the beginning and the evolution of atherosclerosis over its long natural history from endothelial function to clinical events. Many of these risk factors could be common history for both diabetes mellitus and cardiovascular disease, reinforcing the postulate that both disorders come independently from "common soil". The objective of this review is to highlight the weight of traditional and non-traditional risk factors for cardiovascular disease in the setting of type 2 diabetes mellitus and discuss their position in the pathogenesis of the excess cardiovascular disease mortality and morbidity in these patients.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy.

              Laboratory measurements of plasma lipids (principally cholesterol and triglycerides) and lipoprotein lipids (principally low-density lipoprotein [LDL] and low-density lipoprotein [HDL] cholesterol) are the cornerstone of the clinical assessment and management of atherosclerotic cardiovascular disease (CVD) risk. LDL particles, and to a lesser extent very-low-density lipoprotein [VLDL] particles, cause atherosclerosis, whereas HDL particles prevent or reverse this process through reverse cholesterol transport. The overall risk for CVD depends on the balance between the "bad" LDL (and VLDL) and "good" HDL particles. Direct assessment of lipoprotein particle numbers us now possible through nuclear magnetic resonance spectroscopic analysis.
                Bookmark

                Author and article information

                Contributors
                nbhanpuri@virtahealth.com
                hallbers@iuhhealth.org
                1742spyglass@comcast.net
                amy@virtahealth.com
                ballarkd@miamioh.edu
                campbeww@purdue.edu
                jim@virtahealth.com
                steve@virtahealth.com
                jeff@virtahealth.com
                Journal
                Cardiovasc Diabetol
                Cardiovasc Diabetol
                Cardiovascular Diabetology
                BioMed Central (London )
                1475-2840
                1 May 2018
                1 May 2018
                2018
                : 17
                : 56
                Affiliations
                [1 ]Virta Health, San Francisco, CA USA
                [2 ]ISNI 0000 0004 0440 2154, GRID grid.411569.e, Medically Supervised Weight Loss, , Indiana University Health Arnett, ; Lafayette, IN USA
                [3 ]Independent Consultant, Lafayette, CA USA
                [4 ]ISNI 0000 0001 2195 6763, GRID grid.259956.4, Department of Kinesiology and Health, , Miami University, ; Oxford, OH USA
                [5 ]ISNI 0000 0004 1937 2197, GRID grid.169077.e, Department of Nutrition Science, , Purdue University, ; West Lafayette, IN USA
                [6 ]ISNI 0000 0001 2355 7002, GRID grid.4367.6, Department of Genetics, , Washington University School of Medicine, ; St. Louis, MO USA
                [7 ]ISNI 0000 0001 2285 7943, GRID grid.261331.4, Department of Human Sciences, , The Ohio State University, ; Columbus, OH USA
                Author information
                http://orcid.org/0000-0003-4230-3600
                Article
                698
                10.1186/s12933-018-0698-8
                5928595
                29712560
                4485c71d-ff9d-4efa-babe-1473c1c3027f
                © The Author(s) 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 9 February 2018
                : 2 April 2018
                Funding
                Funded by: Virta Health
                Categories
                Original Investigation
                Custom metadata
                © The Author(s) 2018

                Endocrinology & Diabetes
                ketosis,carbohydrate restriction,type diabetes,cardiovascular disease,risk factor,atherogenic dyslipidemia,inflammation,blood pressure,antihypertensive medication,continuous remote care

                Comments

                Comment on this article